Skip to main content
SpringerLink
Log in

Platinum-Based Drugs in Cancer Therapy

  • Book
  • © 2000

Overview

Editors:
  1. Lloyd R. Kelland

    1. CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, UK

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Nicholas P. Farrell

    1. Department of Chemistry, Virginia Commonwealth University, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

  • 4366 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

  1. Front Matter

    Pages i-xii
    Download chapter PDF

  2. Platinum Chemistry

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. The Chemistry of Cisplatin in Aqueous Solution

      • Susan J. Berners-Price, Trevor G. Appleton
      Pages 3-35

    3. Chemistry and Structural Biology of 1,2-Interstrand Adducts of Cisplatin

      • Viktor Brabec
      Pages 37-61

    4. Transplatin-modified Oligonucleotides as Potential Antitumor Drugs

      • Marc Leng, Annie Schwartz, Marie-Josephe Giraud-Panis
      Pages 63-85

  3. Platinum Biochemistry

    1. Front Matter

      Pages 87-87
      Download chapter PDF

    2. Cisplatin Accumulation

      • Paul A. Andrews
      Pages 89-113

    3. Cisplatin Resistance in Ovarian Cancer

      • Robert Brown
      Pages 115-128

    4. DNA Adduct Tolerance and Bypass

      • Stephen G. Chaney, Alexandra Vaisman
      Pages 129-148

    5. How Does Cisplatin Kill Cells?

      • Daniel Fink, Stephen B. Howell
      Pages 149-167

  4. Clinical Antitumor Activity and Toxicology of Platinum Drugs

    1. Front Matter

      Pages 169-169
      Download chapter PDF

    2. Clinical Experience with Cisplatin and Carboplatin

      • Martin S. Highley, A. Hilary Calvert
      Pages 171-194

    3. Clinical Experience

      • Michelle Vaughan, Francisco Sapunar, Martin Gore
      Pages 195-230

    4. Clinical Experience

      • Peter J. O’Dwyer, James P. Stevenson, Steven W. Johnson
      Pages 231-249

    5. Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents

      • Mark J. McKeage
      Pages 251-275

    6. Toxicology and Regulatory Aspects of Platinum Drugs

      • Diana L. Clark, Paul A. Andrews, D. D. Smith, Joseph J. DeGeorge, Robert L. Justice, Julie G. Beitz
      Pages 277-296

  5. New Platinum Drugs of the Future

    1. Front Matter

      Pages 297-297
      Download chapter PDF

    2. New Platinum Drugs

      • Lloyd R. Kelland
      Pages 299-319

    3. Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents

      • Nicholas Farrell
      Pages 321-338

  6. Back Matter

    Pages 339-341
    Download chapter PDF
Back to top

Keywords

About this book

Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair and replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered. Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.

Reviews

This volume of the Cancer Drug Discovery and Development series provides comprehensive coverage of some of the basic science associated with cisplatin, its interaction with DNA and how recognitions and processing of platinum-DNA adducts may be associated with tumour response or resistance. ...Bringing together the most recent research in the area of platinum drugs...The editors of this book have produced a collection of articles which will be of interest to those who need an introduction to the field of platinum drugs. For anyone already familiar with the field, the chapters on the newer analogues and on some of the more recent basic molecular pharmacology issues will provide a useful update. -The Lancet

"The great attention is also paid to all toxicological aspects of platinum drugs from both clinical and regulatory perspective.... The Platinum-based Drugs in Cancer Therapy appears to be a comprehensive book useful for scientist, medical oncologist and pharmacist seeking answer on specific questions concerning preclinical and clinical data of platinum drugs."-Neoplasma

"The strength of the text lies in the diversity of topics that are covered in such a succinct fashion. Clinicians will benefit from the earlier focus on basic chemistry and biochemistry, while the bench scientist will better appreciate the practicalities of using these compounds from the lucid experiences of the clinical case studies."-Journal of Medicinal Chemistry

"This is a useful reference book for scientists and practitioners who have a focus or interest in the chemistry and biochemistry of the platinum compounds. Oncologists will find it helpful for its summary of applications of cisplatin and carboplatin, especially in combination with paclitaxel."--Oncology Journal, November, 2000

"...the book should find its place in the library of many laboratories involved mainly in preclinical oncological research."-Annals of Oncology

"This new bookby Kelland and Farrell is a well-constructed and authoritative account of current knowledge concerning the pharmacology and clinical application of platinum anticancer drugs. It is well illustrated with clear diagrams and appropriate data. ...Not only do platinum agents remain a key component of current cancer therapy for the majority of common solid tumours but recent advances have demonstrated the scope for expansion of the clinical spectrum of activity, the ability to overcome resistance, and the potential introduction of oral delivery." - Clinical Oncology

Editors and Affiliations

  • CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, UK

    Lloyd R. Kelland

  • Department of Chemistry, Virginia Commonwealth University, USA

    Nicholas P. Farrell

Bibliographic Information

  • Book Title: Platinum-Based Drugs in Cancer Therapy

  • Editors: Lloyd R. Kelland, Nicholas P. Farrell

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59259-012-4

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2000

  • Hardcover ISBN: 978-0-89603-599-7Published: 24 March 2000

  • Softcover ISBN: 978-1-61737-091-5Published: 08 December 2010

  • eBook ISBN: 978-1-59259-012-4Published: 24 March 2000

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XII, 341

  • Number of Illustrations: 5 b/w illustrations

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation